乙型肝炎表面抗原水平可识别亚洲非活动性慢性乙型肝炎患者中肝细胞癌风险低于监测阈值者
本研究基于ERADICATE-B和REVEAL-HBV队列2674例非活动性慢性乙型肝炎患者,中位随访26.3年,76例发生肝细胞癌。HBsAg<100 IU/mL者年肝细胞癌发生率为0.08%(95%CI 0.05%至0.13%),低于HBsAg≥100 IU/mL者(调整HR 0.35,95%CI 0.21至0.61),且低于推荐的肝细胞癌监测阈值。
要点
- 非活动性慢性乙型肝炎患者HBsAg<100 IU/mL者年肝细胞癌发生率为0.08%(95%CI 0.05%至0.13%)。
- HBsAg<100 IU/mL者肝细胞癌风险低于HBsAg≥100 IU/mL者(调整HR 0.35,95%CI 0.21至0.61)。
- 联合HBsAg<100 IU/mL与ALT正常可识别肝细胞癌风险可忽略者,无需HBV DNA检测,已在NTUH-iMD队列验证。
核心结论
- 血清HBsAg<100 IU/mL可有效识别肝细胞癌风险可忽略且病毒活动有限的非活动性慢性乙型肝炎患者,对优化监测策略和定义部分HBV治愈具有重要意义。
研究设计与样本
- 分析ERADICATE-B和REVEAL-HBV队列中2674例非活动性慢性乙型肝炎患者(非肝硬化、HBeAg阴性、ALT正常、HBV DNA<2000 IU/mL)数据,主要终点为肝细胞癌发生,用HBsAg水平识别年肝细胞癌风险<0.2%的患者,结果在NTUH-iMD队列验证。
主要发现
- 中位随访26.3年,76例患者发生肝细胞癌。
- 989例HBsAg<100 IU/mL的非活动性慢性乙型肝炎患者年肝细胞癌发生率为0.08%(95%CI 0.05%至0.13%),低于HBsAg≥100 IU/mL者(调整HR 0.35,95%CI 0.21至0.61)。
- HBsAg<100 IU/mL者的肝细胞癌风险低于推荐的肝细胞癌监测阈值,接近一般人群风险。
- 即使对推荐进行肝细胞癌监测的老年患者,HBsAg<100 IU/mL者的肝细胞癌风险也低于监测阈值。
- 联合HBsAg<100 IU/mL与ALT正常可识别肝细胞癌风险可忽略的非活动性慢性乙型肝炎患者,无需HBV DNA检测,已在NTUH-iMD队列验证。
关键数值与推荐
- 非活动性慢性乙型肝炎定义为非肝硬化、HBeAg阴性、ALT正常、HBV DNA<2000 IU/mL。
- 年肝细胞癌风险<0.2%为识别风险可忽略患者的阈值。
- HBsAg<100 IU/mL者年肝细胞癌发生率为0.08%(95%CI 0.05%至0.13%)。
- HBsAg<100 IU/mL vs HBsAg≥100 IU/mL的调整HR为0.35(95%CI 0.21至0.61)。
临床怎么用
- 血清HBsAg<100 IU/mL可用于识别非活动性慢性乙型肝炎中肝细胞癌风险可忽略且病毒活动有限的患者,以优化监测策略并定义部分HBV治愈。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis B (CHB) is a major global health concern primarily due to hepatocellular carcinoma (HCC) development. OBJECTIVE: This study aimed to identify patients with inactive CHB with negligible HCC risk using hepatitis B surface antigen (HBsAg) levels, which is the key to define partial HBV cure. DESIGN: Data from 2674 patients with inactive CHB (non-cirrhotic, hepatitis B e antigen negative, normal alanine transaminase (ALT), HBV DNA <2000 IU/mL) in the ERADICATE-B and REVEAL-HBV cohorts were analysed. The primary endpoint was HCC development, with HBsAg levels used to identify patients with annual HCC risk <0.2%. Results were validated using the NTUH-iMD cohort. RESULTS: Over a median follow-up of 26.3 years, 76 patients developed HCC. Among 989 patients with inactive CHB with HBsAg<100 IU/mL, the annual HCC incidence was 0.08% (95% CI 0.05% to 0.13%), lower than those with HBsAg≥100 IU/mL (adjusted HR 0.35, 95% CI 0.21 to 0.61). Their HCC risk was lower than the recommended threshold for HCC surveillance and was close to the risk of the general population. Even for older patients recommended for HCC surveillance, those with HBsAg levels <100 IU/mL were associated with HCC risk lower than the surveillance threshold. Moreover, patients with inactive CHB with negligible HCC risk could be identified by combining HBsAg <100 IU/mL and normal ALT levels, without the need for HBV DNA testing, as validated in the NTUH-iMD cohort. CONCLUSION: Serum HBsAg levels <100 IU/mL effectively identify patients with inactive CHB with negligible HCC risk and limited viral activity, which is important in optimising surveillance strategies and defining partial HBV cure.
引用
- Tseng TC, Huang SC, Pan MH, et al. Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold. Gut. 2025. PMID: 40541298. doi:10.1136/gutjnl-2025-334911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。